Full Text PA-96-078 NOVEL HIV VACCINE DESIGN NIH GUIDE, Volume 25, Number 33, October 4, 1996 PA NUMBER: PA-96-078 P.T. 34 Keywords: AIDS Vaccine National Institute of Allergy and Infectious Diseases PURPOSE The National Institute of Allergy and Infectious Diseases (NIAID) gives special consideration for funding to scientifically meritorious applications in response to Program Announcements. Our Program Announcements identify areas of ongoing research emphasis for the NIAID. The purpose of this Program Announcement (PA) is to solicit investigator-initiated research to study novel "high risk - high impact" HIV vaccine concepts in early stages of development. HEALTHY PEOPLE 2000 The Public Health Service (PHS) is committed to achieving the health promotion and disease prevention objectives of "Healthy People 2000," a PHS-led national activity for setting priority areas. This Program Announcement (PA), "Novel HIV Vaccine Design", is related to the priority area(s) of immunization and infectious diseases; HIV infection; sexually transmitted diseases. Potential applicants may obtain a copy of "Healthy People 2000" (Full Report: Stock No. 017-001-00474-0 or Summary Report: Stock No. 017-001-00473-1) through the Superintendent of Documents, Government Printing Office, Washington, DC 20402-0325 (telephone 202-783-3238). ELIGIBILITY REQUIREMENTS Applications may be submitted by domestic and foreign, for-profit and non-profit organizations, public and private, such as universities, colleges, hospitals, laboratories, units of State and local governments, and eligible agencies of the Federal government. The total requested project period for an application submitted in response to this PA may not exceed five years; a foreign application may not request more than three years of support and will receive no support for indirect costs. Domestic applications may include international components but these components will receive no support for indirect costs. Racial/ethnic minority individuals, women, and persons with disabilities are encouraged to apply as Principal Investigators. Foreign institutions are not eligible for the First Independent Research Support and Transition (FIRST) award (R29). MECHANISM OF SUPPORT The mechanisms of support will be the individual research project grant (R01), Interactive Research Project Grants (IRPG), the First Independent Research Support Transition (FIRST; R29) award, and the Small Research Grant (R03). Research support may also be obtained through applications for a competitive supplement to ongoing NIH-funded grants. Information on the IRPG mechanism is available in program announcement PA-96-001, published in the NIH Guide, Vol. 24, No. 35, October 6, 1995. NIAID uses R03 grants to support small highly innovative or pilot projects. Applicants for R03 grants must follow application guidelines, SMALL RESEARCH GRANTS - NIAID, which appeared in the NIH Guide, Vol. 25, No. 9, March 22, 1996. Both of these publications are available from NIAID program staff listed under INQUIRIES and on the World Wide Web (http://www.nih.gov/grants/funding/funding.htm). Responsibility for the planning, direction and execution of the proposed project will be solely that of the applicant. Applicants are encouraged to coordinate, through the use of consortium arrangements or subcontracts, integrated approaches with individuals or institutions having relevant reagents and expertise in their use, demonstrated ability in a particular area of relevant research, or access to relevant animal of patient populations. Potential applicants are encouraged to contact the program staff listed under INQUIRIES for guidance concerning both the organization and scope of the proposed work and the preparation of the application itself. RESEARCH OBJECTIVES Background The area of HIV vaccine research and development has been, and continues to be, a major priority for the Division of AIDS NIAID as outlined in the NIAID HIV/AIDS Research Agenda. NIAID continues to be the lead agency within the National Institutes of Health (NIH) for such efforts. Vaccines are probably the best tools ever developed for the prevention of disease, and they are important for both disease control and control of health care costs. The National Cooperative Vaccine Development Groups for AIDS (NCVDG) program is one of the major NIAID efforts to fund investigator-initiated vaccine development. However, vaccine concepts need to be already relatively well-developed to merit funding of these multi-project awards. In contrast, this Program Announcement is designed to encourage and fund the very earliest steps of vaccine development. Major advances in our understanding of the immune system and its response to infectious agents have occurred in recent years. These advances include: characterization of the structure and function of the T lymphocyte receptor for antigen and the numerous accessory molecules involved in the initial signal transduction events; identification and characterization of the numerous cytokines that regulate immune responses; delineation of the steps involved in antigen processing and presentation; definition and characterization of adhesion molecules and their roles in interactions between cells of the immune system; identification of genes that regulate the expression and function of many immune system molecules; and, in several infectious diseases, elucidation of the role (protective vs. pathogenic) played by different arms of the immune response. In addition, advances in the understanding of HIV pathogenesis that may lead new vaccine strategies have recently been made. These include the identification and characterization of HIV coreceptors and the inhibitory effects of chemokines. Research Objectives and Experimental Approaches Examples of novel experimental approaches to HIV immunization that would be responsive to this PA would include live virus vectors, bacterial vector-based vaccines, nucleic acid-based immunogens, adjuvants, and conformational (nonlinear) synthetic peptide vaccine strategies. Vaccination approaches focussing on novel antigen design or vaccine target antigens are also encouraged. Research objectives responsive to this PA would include investigations into the mechanisms of protective immunity required for the development of safe and effective HIV vaccines. Some examples of relevant research objectives are given below; these examples, however, are not intended to be all-encompassing or limiting. o Incorporation of antigen or antigenic peptides into targeting molecules that will more efficiently deliver them to antigen presenting cells or specific lymphoid tissues including mucosal inductive sites o Manipulation of antigen processing and presentation pathways to enhance cell-mediated immunity (e.g.,preferential induction of cytotoxic T lymphocyte (CTL) responses) o Concomitant administration of appropriate cytokines or costimulatory molecules with antigens to enhance specific immune effector functions (e.g., Th1 [type 1] vs. Th2 [type 2] immune responses and immunoglobulin isotypes) or to enhance mucosal responses. Vaccine concepts that are already being tested in primate models or in clinical trials would not be responsive to this PA. INCLUSION OF WOMEN AND MINORITIES IN RESEARCH INVOLVING HUMAN SUBJECTS It is the policy of the NIH that women and members of minority groups and their sub-populations must be included in all NIH supported biomedical and behavioral research projects involving human subjects, unless a clear and compelling rationale and justification is provided that inclusion is inappropriate with respect to the health of the subjects or the purpose of the research. This new policy results from the NIH Revitalization Act of 1993 (Section 492B of Public Law 103-43) and supersedes and strengthens the previous policies (Concerning the Inclusion of Women in Study Populations, and Concerning the Inclusion of Minorities in Study Populations), which have been in effect since 1990. The new policy contains some provisions that are substantially different from the 1990 policies. All investigators proposing research involving human subjects should read the "NIH Guidelines For Inclusion of Women and Minorities as Subjects in Clinical Research," which have been published in the Federal Register of March 28, 1994 (FR 59 14508-14513) and printed in the NIH Guide for Grants and Contracts, Volume 23, Number 11, March 18, 1994. Investigators also may obtain copies of the policy from the program staff listed under INQUIRIES. Program staff may also provide additional relevant information concerning the policy. APPLICATION PROCEDURES Applications are to be submitted on the grant application form PHS 398 (rev. 5/95) and will be accepted on the standard application deadlines as indicated in the application kit. Application kits are available at most institutional offices of sponsored research and may be obtained from the Grants Information Office, Office of Extramural Outreach and Information Resources, National Institutes of Health, 6701 Rockledge Drive, MSC 7910, Bethesda, MD 20892-7910, telephone (301)710-0267, email: asknih@odrockm1.od.nih.gov. The title and number of this program announcement must be typed in Section 2 on the face page of the application. The completed original and five legible, single-sided copies of the application must be sent or delivered to: DIVISION OF RESEARCH GRANTS NATIONAL INSTITUTES OF HEALTH 6701 ROCKLEDGE DRIVE, ROOM 1040, MSC 7710 BETHESDA, MD 20892-7710 BETHESDA, MD 20817-7710 (for express/courier service) FIRST (R29) applications must include at least three sealed letters of reference attached to the face page of the original application. FIRST applications submitted without the required number of reference letters will be considered incomplete and will be returned without review. Applicants from institutions that have a Center for AIDS Research (CFAR) or a General Clinical Research Center (GCRC) funded by the NIH National Center for Research Resources may wish to identify the Center as a resource for conducting the proposed research. If so, a letter of agreement from the Center Program Director must be included in the application material. REVIEW CONSIDERATIONS Applications will be assigned on the basis of established PHS referral guidelines. Applications will be reviewed for scientific and technical merit in accordance with the standard NIH peer review procedures. As part of the initial merit review, all applications will receive a written critique and undergo a process in which only those applications deemed to have the highest scientific merit, generally the top half of the applications under review will be discussed, assigned a priority score, and receive a second level review by the appropriate national advisory council or board. Review Criteria o Scientific, technical, or medical significance and originality of the proposed research; o Appropriateness and adequacy of the experimental approach and methodology proposed to carry out the research; o Qualifications and research experience of the Principal Investigator and staff, particularly, but not exclusively, in the area of the proposed research; o Availability of the facilities and resources necessary to perform the research; o Appropriateness of the proposed budget and duration in relation to the proposed research; o Adequacy of plans to include both genders and minorities and their subgroups as appropriate for the scientific goals of the research. Plans for the recruitment and retention of subjects will also be evaluated. The initial review group will also examine the provisions for the protection of human and animal subjects, the safety of the research environment. AWARD CRITERIA Applications will compete for available funds with all other favorably recommended applications. The following will be considered when making funding decisions: o quality of the proposed project as determined by peer review o program balance among research areas of the announcement o availability of funds INQUIRIES Written and telephone inquiries are encouraged. The opportunity to clarify any issues or questions from potential applicants is welcome. Direct inquiries regarding programmatic (eligibility and responsiveness) issues to: Frederick R. Vogel, Ph.D. Division of AIDS National Institute of Allergy and Infectious Diseases 6003 Executive Boulevard, Room 2A28A - MSC-7620 Bethesda, MD 20892-7620 Telephone: (301) 402-0121 FAX: (301) 402-3684 Email: FV1V@nih.gov Direct inquiries regarding fiscal matters to: Ms. Lesia Norwood Division of Extramural Activities National Institute of Allergy and Infectious Diseases 6003 Executive Boulevard, Room 4B34 - MSC 7610 Bethesda, MD 20892-7610 Telephone: (301) 496-7075 FAX: (301) 480-3780 Email: LN5T@nih.gov AUTHORITY AND REGULATIONS This program is supported under authorization of the Public Health Service Act, Sec. 301 (c), Public Law 78-410, as amended. The Catalogue of Federal Domestic Assistance Citation is 93.856, Microbiology and Infectious Diseases Research, No. 93.855 - Immunology, Allergy, and Transplantation Research, or both, as appropriate). Awards will be administered under PHS grants policies and Federal Regulations 42 CFR Part 52 and 45 CFR Part 74. This program is not subject to the intergovernmental review requirements of Executive Order 12372 or Health Systems review. The PHS strongly encourages all grant and contract recipients to provide a smoke-free workplace and promote the non-use of all tobacco products. In addition, Public Law 103-227, the Pro-Children Act of 1994, prohibits smoking in certain facilities (or in some cases, any portion of a facility) in which regular or routine education, library, day care, health care or early childhood development services are provided to children. This is consistent with the PHS mission to protect and advance the physical and mental health of the American people. .
Return to NIH Guide Main Index
Office of Extramural Research (OER) |
National Institutes of Health (NIH) 9000 Rockville Pike Bethesda, Maryland 20892 |
Department of Health and Human Services (HHS) |
||||||||
Note: For help accessing PDF, RTF, MS Word, Excel, PowerPoint, Audio or Video files, see Help Downloading Files. |